John Butler, Akebia CEO
Akebia touts new data on anemia drug a year after rejection
Akebia Therapeutics is back with more data on its experimental anemia drug vadadustat following a CRL from the FDA last year …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
